本研究所使用的RRx-001是一种能够穿透血脑屏障的小分子,它作为一种NLRP3抑制剂,同时能在在缺氧条件下产生一氧化氮使肿瘤相关巨噬细胞极化,并使肿瘤血管正常化。 该分子已获得FDA批准用于头颈部癌症治疗,目前正在进行小细胞肺癌(SCLC)的III期临床试验。本试验G-FORCE-1 (NCT02871843)作为一项多中心剂量递增的I期临...
近日,EpicentRx公布了NLRP3抑制剂RRx-001在结直肠癌患者中进行的ROCKET临床试验数据,本文将为您介绍相关内容。 关于结直肠癌RRx-001 RRx-001是一款具有First-in-Class(FIC)潜质的小分子药物,具有多种作用机制,包括CD47-SIRPα靶向、RONS生成以及表观遗传调节。RRx-001可以对多种肿瘤微环境异常起到调节作用,包括:下调...
美国食品和药物管理局(FDA)授予RRx-001快速通道指定,RRx-001是一种直接NLRP3抑制剂和Nrf2上调剂,具有抗-炎症和抗氧化特性,用于预防/减轻化疗和放疗头颈癌患者的严重口腔粘膜炎。 什么是RRx-001? RRx-001是一种高选择性NLRP3抑制剂,目前正在研究治疗小细胞肺癌(SCLC)的3期试验,以及一项计划在一线头颈癌中预防口腔...
美国食品和药物管理局FDA于近日授予RRx-001快速通道称号,用于预防和减轻头颈部癌症患者化疗和放疗引起的严重口腔黏膜炎。港安健康国际医疗介绍,RRx-001是一种直接的NLRP3抑制剂和Nrf2上调剂,具有抗炎和抗氧化特性,目前也在研究用于治疗小细胞肺癌。 研究人员先前在2a期PREVLAR试验(NCT03515538)中评估了RRx-001。2研究...
001 is a highly selective and potent NLRP3 inhibitor that has strong beneficial effects on NLRP3-driven inflammatory diseases.RRx-001 inhibits the activation of the canonical,noncanonical,and alternative NLRP3 inflammasomes but not the AIM2,NLRC4 or Pyrin inflammasomes.Mechanistically,RRx-001 ...
与"RRX-001"相关的抑制剂 Stavudine 司他夫定, Sanilvudine, NSC 163661, d4T, BMY-27857 T14043056-17-5 Stavudine (BMY-27857) 是一种口服活性核苷逆转录酶抑制剂,还抑制线粒体 DNA 的复制,具有抗HIV-1和HIV-2的活性。它降低 NLRP3 炎症小体激活,调节淀粉样 β 自噬,诱导细胞凋亡。
RRx-001NLRP3 inflammasomeNrf2KEAP1nitric oxideantibody drug conjugate (ADC)NFkBRRx-001 is a shape shifting small molecule with Fast Track designation for the prevention/amelioration of chemoradiation-induced severe oral mucositis (SOM) in newly diagnosed Head and Neck cancer. It has been ...
In these experiments, we investigated whether RRx-001, a NO donor only under hypoxia and an NLRP3 inflammasome inhibitor, in a Phase 3 trial (REPLATINUM; NCT03699956) for the treatment of cancer was protective after MI. Methods: Male Sprague-Dawley rats (n=8/group) subjected to coronary ...
NLRP3 proteinBackground: Bromonitrozidine (RRx-001) is a minimally toxic, NLRP3 inhibitor that has been observed, in experimental systems, to also downregulate CD47, repolarize tumor associated macrophages (TAMs) and normalize aberrant tumor perfusion. This phase 1 pilot...
Several NLRP3 inflammasome inhibitors are in development, all with multi-indication activity. This review discusses the current status, known mechanisms of action, and disease-modifying therapeutic potential of RRx-001, a direct NLRP3 inflammasome inhibitor under investigation in several late-stage ...